To anticoagulate or not to anticoagulate patients with cardiomyopathy

Cardiology Clinics

Volumn 19, Issue 4, 2001, Pages 605-615

  Graham, Susan P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; CARDIOMYOPATHY; DRUG ANTAGONISM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SKIN NECROSIS; STROKE; SUDDEN DEATH; THROMBOSIS; TREATMENT OUTCOME;

EID: 0034758856     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70247-2     Document Type: Article

References (93)

1. Gender differences in survival in advanced heart failure: Insights from the FIRST Study
2. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction
3. The prevalence of ulcerated plaques in the aortic arch in patients with stroke
4. Effect of prophylactic amiodarone on mortality, after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6,500 patients in randomized trials
5. Low grade exercise enhances platelet aggregability in patients with obstructive coronary disease independent of myocardial ischemia
6. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
7. Risk factors for stroke and efficacy of antithrombolic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
8. Randomized placebo controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
9. Possible interaction between aspirin and ACE inhibitors: Update on unresolved controversy
10. Variations in family physicians' and cardiologists' care for patients with heart failure
11. Impact of ACE inhibitors/AT I receptor blockade on renal function in heart failure
12. A multicomponant intervention to prevent major bleeding complications in older patients receiving warfarin
13. Secondary prevention of sudden death: The Dutch study, the antiarrhythmics versus implantable defibrillator trial, the cardiac arrest study Hamburg and the Canadian implantable defibrillatory Study
14. Lack of correlation between intracavitary thrombosis detected by cross-sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy
15. The cardiac insufficiency bisoprolol study II: A randomized trial
16. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina
17. Is aspirin safe for patients with heart failure?
18. Renal syndromes associated with nonsteroidal antiinflammatory drugs
19. A comparison of enalapril with hydralazine-isosorbide dinitrate on the treatment of chronic congestive heart failure
20. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS)
21. Randomized double-blind trial of fixed lowdose warfarin with aspirin after myocardial infarction
22. Oral anticoagulation self-management and management by a specialist anti-coagulation clinic: A randomized cross-over comparison
23. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure
24. Anatomic features in victims of sudden coronary death: Coronary artery pathology
25. Internal analgesic, antipyretic, and antirheumatic drug products for overthe-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid products
26. The effect of digoxin on mortality and morbidity in patients with heart failure
27. Ramdomized trial of low dose amiodarone in severe congestive heart failure
28. Racial differences in the outcome of left ventricular dysfunction
29. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials
30. Incidence of thromboembolic events in congestive heart failure
31. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
32. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The cardiac arrhythmia suppression trial
33. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
34. A plea for a trial of anticoagulation in dilated cardiomyopathy
35. Sudden coronary death: Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction
36. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy
37. Risk factors for complications of chronic anticoagulation
38. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation
39. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
40. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA study)
41. Metoprolol CR/XL randomized intervention trial in CHF (Merit-HF): An update after completed randomization: Abstracts from the 71st scientific session
42. Prevention of first stroke
43. Hemodynamic interaction of aspirin with enalapril
44. Guidelines for the evaluation and management of heart failure
45. Profile and prevalence of aspirin resistance among patients with heart disease: A prospective, comprehensive assessment
46. The aspirin-angiotensive-converting enzyme inhibitor tradeoff: To halve and halve not
47. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
48. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe heart failure
49. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure
50. Stroke with intermittent atrial fibrillation: Incidence and prediction during aspirin therapy
51. Clopidogrel, a novel antiplatelet and antithrombotic agent
52. Risk factors for the intracranial hemorrhage in outpatients taking warfarin
53. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
54. Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy
55. Low incidence of stroke in ambulatory patients with heart failure: A prospective study
56. Movahed A: Role of ß-blockers in congestive heart failure
57. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD:HEFT and MADIT-II
58. Prospective randomized comparison of effects of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
59. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
60. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin
61. Aspirin and mortality in patients treated with angiotensinconverting enzyme inhibitors
62. Does heart failure confer a hypercoagulable state? Virchow's triad revisted
63. Ventricular dysfunction predicts stroke following myocardial infarction
64. Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease
65. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
66. Is major stroke worse than death?: Results from a survey of preferences among persons at increased risk for stroke
67. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
68. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
69. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
70. Consumption of NSAIDs and the development of congestive heart failure in elderly patients
71. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: The GUSTO-1 Trial
72. Overview of angiotensin II receptor antagonists
73. Prostaglandins and prostaglandin inhibitors in ischemic heart disease
74. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
75. Multicentre randomized study of computerized anticoagulant dosage
76. Stroke in patients with heart failure and reduced left ventricular ejection
77. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the physicians' health study
78. Predictability of left ventricular thrombus by mitralregurgitation
79. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction
80. The effect of warfarin on mortality and reinfarction after myocardial infarction
81. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
82. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
83. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of a double-blind, randomized comparative trial
84. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?
85. New onset heart failure in the outpatient setting: Characteristics and outcomes of patients with low and preserved ejection fraction
86. Beyond drug therapy: Nonpharmacologic care of the patient with advanced heart failure
87. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking?
88. Acute coronary findings at autopsy in heart failure patients with sudden death
89. Effect dsotalol on mortality in patients with left ventricular dysfunction after recent and remove myocardial infarction
90. The WASH study (Warfarin/Aspirin study in heart failure) rationale, design and end-points
91. Effects of candesartan, enalapril or their combinations on exercise capacity, ventricular function, clinical deterioration, and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD)
92. Left ventricular dysfunction: A clue to cognitive impairment in older patients with heart failure